abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

This page is not available in Deutsch and is being displayed in English

Artikel

12 Dez 2007

Autor*in:
Compiled by the Business & Human Rights Resource Centre

Oxfam report "Investing for Life": Company responses

The Business & Human Rights Resource Centre invited all 12 [pharmaceutical] companies to respond to the report. The results to date are below (any future responses received will be added to this page)...On 6 February 2008 Oxfam sent a rejoinder, commenting on the company responses... - Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis responded - Roche, Eli Lilly declined to respond - Bristol-Myers Squibb, Wyeth did not respond

Story Timeline